Immunosyn Announces Proposed Agreements for Distribution of the Biopharmaceutical SF-1019 in Utah
July 16 2008 - 9:00AM
PR Newswire (US)
LA JOLLA, Calif., July 16 /PRNewswire-FirstCall/ -- Immunosyn
Corporation (OTC:IMYN) (BULLETIN BOARD: IMYN) announced today that
the distribution of SF-1019 in the State of Utah is anticipated to
begin shortly through Renewed Hope Clinic in Beaver, Utah.
Immunosyn is negotiating an exclusive license agreement for the
administration and distribution of SF-1019 in the State of Utah
with Utah Biopharmaceutical Laboratories, LLC. Immunosyn has been
advised by Argyll Biotechnologies, LLC, the licensor of SF-1019,
Immunosyn's strategic partner and its largest shareholder, that
Argyll Biotech is negotiating a three-party agreement with its
current domestic third party manufacturer and Utah
Biopharmaceutical Laboratories for Utah Biopharmaceuticals
Laboratories to be a third party manufacturer of SF-1019 in the
State of Utah. Argyll Biotech has worked for several years on
developing the manufacturing processes, protocols, safety
procedures and guidelines for SF-1019. Immunosyn, together with
Argyll Biotech and Utah Biopharmaceutical Laboratories, is working
to finalize Distribution Management and Information Component
Systems that will be implemented to define protocols to assure
patient safety and regulatory compliance in Utah prior to treatment
commencing. The combination of the proposed license and
manufacturing agreements will allow for SF-1019 to be administered
in the State of Utah exclusively by Utah Biopharmaceutical
Laboratories through Renewed Hope Clinic which is located in
Beaver, Utah. "I am excited to have the ability to treat patients
with this therapeutic modality, which is not yet available
elsewhere in the U.S. My review of the scientific background,
preclinical testing, initial safety evaluations and studies
performed under compassionate waivers, coupled with the therapeutic
benefits I have witnessed, give me confidence in the benefit my
patients will receive from SF-1019 treatment," said Mitchell J.
Melling, MD, Manager of Utah Biopharmaceutical Laboratories, LLC.
Stephen D. Ferrone, President and CEO of Immunosyn, stated, "Utah
Biopharmaceutical Laboratories sought the ability to distribute
SF-1019 in the State of Utah as a result of the compelling desire
of patients who are seeking this treatment after their having
failed conventional, FDA approved therapy. This patient demand
stemmed from the perceived benefit of treatment in patients who
participated in early preclinical studies and who desire ongoing
access to SF-1019 to alleviate their symptoms." Ferrone added,
"Argyll Biotech advises us that they plan to continue the process
to obtain full regulatory approvals for the marketing of SF-1019 in
both Europe and the U.S." "This is an exciting early-stage
development as this puts revenue producing capabilities within
short-term range for the company," stated Douglas A. McClain, Jr.,
Chairman of the Board and CFO of Immunosyn. About Utah
Biopharmaceutical Laboratories, LLC Utah Biopharmaceutical
Laboratories was organized for the purpose of manufacturing SF-1019
for administering and distributing by United Biopharmaceutical
Laboratories through the Renewed Hope Clinic under the direction of
Mitchell J. Melling, MD in the State of Utah. About Renewed Hope
Clinic Located in Beaver, Utah at 95 North 400 East, Renewed Hope
Clinic is managed by Mitchell Melling, MD who is Board Certified in
Family Practice in the State of Utah. Renewed Hope Clinic is a
family practice center, emphasizing treatment of autoimmune and
infectious diseases. About Immunosyn Corporation La Jolla,
CA-headquartered Immunosyn Corporation (OTC:IMYN) (BULLETIN BOARD:
IMYN) plans to market and distribute life enhancing therapeutics.
Currently, the company has exclusive worldwide rights from its
largest shareholder, Argyll Biotechnologies, LLC, to market, sell
and distribute SF-1019, a compound that was developed from
extensive research into Biological Response Modifiers (BRMs).
Argyll Biotechnologies, LLC has initiated the process for
regulatory approval of SF-1019 in several countries and
preparations for clinical trials are underway in both the U.S. and
Europe. Research suggests that SF-1019 has the potential to affect
a number of clinical conditions including complications from
Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic
ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS)
and neurological disorders such as Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic
Dystrophy Syndrome (RSD or RSDS). (For more information on
Immunosyn and SF-1019 go to http://www.immunosyn.com/). The above
news release contains forward-looking statements. These statements
are based on assumptions that management believes are reasonable
based on currently available information, and include statements
regarding the intent, belief or current expectations of the Company
and its management. Prospective investors are cautioned that any
such forward-looking statements are not guarantees of future
performance, and are subject to a wide range of business risks,
external factors and uncertainties. Actual results may differ
materially from those indicated by such forward-looking statements.
For additional information, please consult the Company's most
recent public filings and Annual Report on Form 10-K for its most
recent fiscal year. The Company assumes no obligation to update the
information contained in this press release, whether as a result of
new information, future events or otherwise. DATASOURCE: Immunosyn
Corporation CONTACT: Lisa Baker, or Devon Blaine, both of The
Blaine Group, +1-310-360-1499, fax, +1-310-360-1498, , for
Immunosyn Corporation Web site: http://www.immunosyn.com/
Copyright